Fetal stem cells inhaled to fight COPD?
NCT ID NCT07477600
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether infusions of clonal fetal mesenchymal stem cells (cfMSCs) are safe and can help control severe symptoms in people with moderate to severe COPD. About 30 adults aged 40-80 who have not responded well to standard treatments will receive the cells. The main goal is to check for side effects, and researchers will also measure changes in lung function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
clonal fetal mesenchymal stem cells (cfMSCs)
What this could lead to
If it works, this could point toward a new way to control COPD symptoms and improve lung function for people who don't respond to standard treatments.
What could go wrong
This is a very early (Phase 1/2) trial with only 30 people, so it's mainly checking safety. The stem cells are experimental, and it's unknown if they will provide lasting benefit or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••